Brean Murray initiates coverage on Alexion Pharmaceutical (Nasdaq: ALXN) with a Buy. Price target $42.

Brean analyst says, "We use ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE